{
  "abstract": "Autoantibodies neutralizing type I IFNs (AAN–IFN-I) have been found in significant proportions of cases of severe, critical, and fatal COVID-19 pneumonia. We performed a systematic review of 54 studies reporting auto-Abs against type I IFNs and a meta-analysis of 20 studies reporting auto- Abs neutralizing type I IFNs published between 2020 and 2026. The meta-analysis included data for 11,380 SARS-CoV-2-infected individuals from Europe, North America, South America, Asia, the Middle East, North Africa and international multicenter cohorts, including 7,814 with severe or critical disease (69%). The pooled prevalence of AAN–IFN-I was estimated at 7.9% (95% CI, 6.0–10.4). Disease severity was strongly associated with AAN–IFN-I prevalence (OR, 11.7; 95% CI, 7.6–17.9; P =5×10⁻²⁹). The pooled prevalence of AAN-IFN-I reached 11.4% (95% CI, 10.2– 12.7%) in patients with severe or critical COVID-19 and 15.3% (95% CI, 12.1–19.2%) in those who died. The prevalence of AAN–IFN-I increased with age in patients with severe, critical, or fatal COVID-19. AAN-IFN-I probably accounted for about 1.1 million of the 7.1 million deaths from COVID-19. AAN-IFN-I are strong, common, global determinants of life-threatening COVID-19 pneumonia.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "name": "Elsa Feredj"
    },
    {
      "name": "Qian Zhang"
    },
    {
      "name": "Paul Bastard"
    },
    {
      "name": "Jean-Laurent Casanova"
    },
    {
      "name": "Aurélie Cobat"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/3aah2s9f2djrf.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.08.06.26359907",
  "fulltext_url": null,
  "id": "3aah2s9f2djrf",
  "issns": [],
  "landing_url": "https://hal.science/hal-05863798v1",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2725|COVID-19 Clinical Research Studies"
    ]
  ],
  "openalex": "W7202074938",
  "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2026/08/10/2026.08.06.26359907.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-08-10",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/3aah2s9f2djrf.ris",
  "sources": [
    {
      "first_seen": "2026-11-14T12:20:48Z",
      "native_id": "hal-05863798",
      "source": "hal",
      "url": "https://hal.science/hal-05863798v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2725|COVID-19 Clinical Research Studies",
      "subfield": "infectious-disease"
    }
  ],
  "title": "Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020–2026",
  "title_text": "Autoantibodies neutralizing type I interferons in patients with life-threatening COVID-19 pneumonia: a meta-analysis from 2020–2026",
  "type": "preprint",
  "updated_at": "2026-11-15T12:20:47Z",
  "url": "https://research.draconitic.com/paper/3aah2s9f2djrf",
  "venue": "Medrxiv : the Preprint Server For Health Sciences",
  "versions": []
}